Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD · IEX Real-Time Price · USD
0.840
0.00 (-0.02%)
At close: Jul 19, 2024, 4:00 PM
0.780
-0.060 (-7.12%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.
The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 14, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 70 |
| CEO | Dr. Lishan Aklog M.D. |
Contact Details
Address: 360 Madison Avenue, 25th Floor New York, New York 10017 United States | |
| Phone | 212 949 4319 |
| Website | luciddx.com |
Stock Details
| Ticker Symbol | LUCD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001799011 |
| CUSIP Number | 54948X109 |
| ISIN Number | US54948X1090 |
| Employer ID | 82-5488042 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lishan Aklog M.D. | Chairman and Chief Executive Officer |
| Shaun M. O'Neill M.B.A. | President and Chief Operating Officer |
| Dennis M. McGrath CPA | Chief Financial Officer |
| Dr. Sanford D. Markowitz M.D., Ph.D. | Cofounder and Strategic Advisor, Member of the Medical Advisor Board |
| Dr. Joseph Willis M.D. | Cofounder, Strategic Advisor and Member of Medical Advisory Board |
| Dr. Amitabh Chak M.D. | Cofounder, Strategic Advisor and Member of Medical Advisory Board |
| Richard D. Yazbeck | Chief Technology Officer |
| Dr. Suman M. Verma M.D., Ph.D. | Chief Scientific Officer |
| Dr. Brian J. deGuzman M.D. | Chief Compliance Officer |
| Michael Adam Gordon | General Counsel and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 19, 2024 | 424B3 | Prospectus |
| Jul 18, 2024 | EFFECT | Notice of Effectiveness |
| Jul 12, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Jul 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jul 1, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 21, 2024 | 8-K | Current Report |
| Jun 6, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 6, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 24, 2024 | PRE 14A | Other preliminary proxy statements |
| May 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |